Tag
Cohance Lifesciences Limited
2 articles
Cohance Lifesciences Invests USD 18M in ADC Strategy
Cohance Lifesciences announces USD 18 million investment in NJ Bio and Aruka Bio to advance its Antibody-drug Conjugate strategy.
Investment includes USD 13M to increase NJ Bio stake to 67.3% and USD
Cohance Lifesciences Invests $18M in NJ Bio and Aruka Bio
Cohance Lifesciences' IBA Committee approved $18M in strategic ADC investments to increase stake in subsidiary NJ Bio from 56% to 67.3% and acquire 65% control of Aruka Bio.
The $13M NJ Bio transactio